CA2702256C - Dispiro 1,2,4-trioxolane antimalarials - Google Patents

Dispiro 1,2,4-trioxolane antimalarials Download PDF

Info

Publication number
CA2702256C
CA2702256C CA2702256A CA2702256A CA2702256C CA 2702256 C CA2702256 C CA 2702256C CA 2702256 A CA2702256 A CA 2702256A CA 2702256 A CA2702256 A CA 2702256A CA 2702256 C CA2702256 C CA 2702256C
Authority
CA
Canada
Prior art keywords
trioxolane
cis
dispiro
mmol
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2702256A
Other languages
English (en)
French (fr)
Other versions
CA2702256A1 (en
Inventor
Jonathan L. Vennerstrom
Yuxiang Dong
Susan A. Charman
Sergio Wittlin
Jacques Chollet
Darren J. Creek
Xiaofang Wang
Kamaraj Sriraghavan
Lin Zhou
Hugues Matile
William N. Charman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MMV Medicines for Malaria Venture
Original Assignee
MMV Medicines for Malaria Venture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MMV Medicines for Malaria Venture filed Critical MMV Medicines for Malaria Venture
Publication of CA2702256A1 publication Critical patent/CA2702256A1/en
Application granted granted Critical
Publication of CA2702256C publication Critical patent/CA2702256C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/02—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2702256A 2007-10-31 2008-10-29 Dispiro 1,2,4-trioxolane antimalarials Active CA2702256C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/930,606 US8067620B2 (en) 2005-05-04 2007-10-31 Dispiro 1,2,4-trioxolane antimalarials
US11/930,606 2007-10-31
PCT/US2008/081579 WO2009058859A2 (en) 2007-10-31 2008-10-29 Dispiro 1,2,4-trioxolane antimalarials

Publications (2)

Publication Number Publication Date
CA2702256A1 CA2702256A1 (en) 2009-05-07
CA2702256C true CA2702256C (en) 2017-09-26

Family

ID=40228026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702256A Active CA2702256C (en) 2007-10-31 2008-10-29 Dispiro 1,2,4-trioxolane antimalarials

Country Status (19)

Country Link
US (1) US8067620B2 (https=)
EP (1) EP2203457B1 (https=)
JP (1) JP5559057B2 (https=)
KR (1) KR101588468B1 (https=)
CN (1) CN101842377B (https=)
AU (1) AU2008318819C1 (https=)
BR (1) BRPI0818121B8 (https=)
CA (1) CA2702256C (https=)
CY (1) CY1115148T1 (https=)
DK (1) DK2203457T3 (https=)
ES (1) ES2466319T3 (https=)
HR (1) HRP20140435T1 (https=)
MX (1) MX2010004601A (https=)
PL (1) PL2203457T3 (https=)
PT (1) PT2203457E (https=)
RU (1) RU2493159C2 (https=)
SI (1) SI2203457T1 (https=)
UA (1) UA99742C2 (https=)
WO (1) WO2009058859A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
KR101886467B1 (ko) 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
JP2015525224A (ja) * 2012-06-13 2015-09-03 メディツィニッシェ ウニヴァズィテート ヴィーン アミドフェノキシプロパノールアミン
WO2015123595A1 (en) 2014-02-14 2015-08-20 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
CA3040335A1 (en) 2016-10-13 2018-04-19 Mmv Medicines For Malaria Venture New anti-malarial agents
EP3309156A1 (en) 2016-10-13 2018-04-18 MMV Medicines for Malaria Venture New anti-malarial agents
WO2018213220A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Ozonides for treating or preventing virus infections
WO2019005977A1 (en) 2017-06-27 2019-01-03 The Regents Of The University Of California Trioxolane agents
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621062A (en) 1966-10-25 1971-11-16 Sterling Drug Inc 2-(8-cyclohexyloctanoyl or 7-cyclohexylheptanoyl)-1-naphthol
US3673222A (en) 1969-11-26 1972-06-27 Sydney Archer 2-(8-cyclohexyloctyl or 7-cyclohexylheptyl)-1,4-naphthoquinone and process for preparation and use thereof
US3682991A (en) 1970-10-19 1972-08-08 Sterling Drug Inc 3,3,5-trimethylcyclohexyl-alkyl-carboxylic acids
US4978678A (en) * 1986-11-20 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 12-halogenated forskolin derivatives
US4916204A (en) 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US4816478A (en) 1987-08-24 1989-03-28 Thornfeldt Carl R Treatment of acquired immunodeficiency syndrome
US5053342A (en) 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
US5270344A (en) 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
JP2867529B2 (ja) 1990-01-22 1999-03-08 三菱電機株式会社 投写型表示装置
US5216175A (en) 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5219880A (en) 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
US5510356A (en) 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria
US5171676A (en) 1991-10-31 1992-12-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of introducing hydroxyl groups into artemisinin and its derivatives
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
JP3567990B2 (ja) 1992-07-28 2004-09-22 ザ、プロクター、エンド、ギャンブル、カンパニー 架橋陽イオン重合体とアルコキシ化エーテルとを含有する局所用途用医薬組成物
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5780675A (en) 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5578637A (en) 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5672624A (en) 1995-11-22 1997-09-30 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5817692A (en) 1995-11-22 1998-10-06 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5932591A (en) 1996-12-02 1999-08-03 Johns Hopkins University C3 substituted trioxanes useful as antiparasitic drugs
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
US20090042821A1 (en) * 2005-05-18 2009-02-12 Arno Appavoo Enose Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Also Published As

Publication number Publication date
JP5559057B2 (ja) 2014-07-23
AU2008318819B2 (en) 2013-11-21
DK2203457T3 (da) 2014-05-12
EP2203457B1 (en) 2014-03-05
US20080125411A1 (en) 2008-05-29
BRPI0818121B8 (pt) 2021-05-25
ES2466319T3 (es) 2014-06-17
HK1147092A1 (en) 2011-07-29
EP2203457A2 (en) 2010-07-07
PT2203457E (pt) 2014-06-06
CY1115148T1 (el) 2016-12-14
PL2203457T3 (pl) 2014-08-29
CN101842377B (zh) 2015-07-01
BRPI0818121B1 (pt) 2020-12-08
CN101842377A (zh) 2010-09-22
HRP20140435T1 (hr) 2014-06-20
WO2009058859A3 (en) 2009-06-18
RU2010121919A (ru) 2011-12-10
BRPI0818121A2 (pt) 2015-11-17
KR20100087199A (ko) 2010-08-03
SI2203457T1 (sl) 2014-06-30
AU2008318819C1 (en) 2014-04-24
US8067620B2 (en) 2011-11-29
JP2011502131A (ja) 2011-01-20
KR101588468B1 (ko) 2016-01-25
MX2010004601A (es) 2010-05-27
UA99742C2 (en) 2012-09-25
AU2008318819A1 (en) 2009-05-07
RU2493159C2 (ru) 2013-09-20
WO2009058859A2 (en) 2009-05-07
CA2702256A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CA2702256C (en) Dispiro 1,2,4-trioxolane antimalarials
EP1414813B1 (en) 1,2,4-trioxolane antimalarials
WO2009091433A2 (en) Spiro and dispiro 1,2,4-trioxolane antimalarials
AU2002327183A1 (en) 1,2,4-trioxolane antimalarials
US20040186168A1 (en) Spiro and dispiro 1,2,4-trioxolane antimalarials
AU2004203864B2 (en) Spiro and dispiro 1,2,4,- trioxolane antimalarials
AU2013273836A1 (en) Dispiro 1,2,4-trioxolane antimalarials
HK1147092B (en) Dispiro 1,2,4-trioxolane antimalarials

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130916

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020